Market Overview

Jazz Pharmaceuticals Sees FY 2012 Adjusted EPS of $4.00 – 4.15 vs $3.40 Est

Jazz Pharmaceuticals (Nasdaq: JAZZ) today provided full year financial guidance for 2012 reflecting the planned business combination with Azur Pharma Public Limited Company, which the companies are targeting to close during the week of January 16, 2012. The company also announced that the Hart-Scott-Rodino waiting period has expired.

Total revenues: $465 – 490 million

Adjusted net income per diluted share $4.00 – 4.15

Posted-In: News Guidance

 

Most Popular

Related Articles (JAZZ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free

Benzinga Professional